Information on Penile Cancer
Penile cancer is one of the least common types of cancer, representing less than 1 percent of all cancer diagnoses in American men every year. While this type of cancer can develop anywhere in the penis, most often it develops in the skin and is classified as either squamous cell carcinoma, melanoma or basal cell carcinoma. However, certain rare variations can develop in the blood vessels or connective tissues (sarcomas) or the sweat glands (adenocarcinomas).
How Moffitt doctors approach penile cancer treatment
As one of the largest cancer centers in the nation based on patient volume, Moffitt Cancer Center has extensive experience diagnosing and treating male genitourinary cancers, including cancers of the penis. Nationally recognized for our comprehensive, multispecialty approach to treatment, we offer a number of advanced penile cancer therapies, including:
- Cryosurgery, which destroys cells through the application of liquid nitrogen
- Laser therapy, which targets tumors with powerful beams of light
- Radiation therapy, which uses high-energy X-rays to treat penile cancer
- Chemotherapy, which uses powerful medications to stop or slow a tumor’s growth
- Surgery, which removes cancerous cells from the penis
Our robust clinical trials program and multispecialty team
Our patients also have the option to participate in clinical trials, which compare the newest penile cancer treatments to the currently available options. Past studies have helped oncologists make several important advances, such as maintaining sensation and urinary function after treatment. For our extensive research efforts, we have been named a Comprehensive Cancer Center by the National Cancer Institute.
Additionally, we provide patients with multiple expert opinions in a single, convenient location. An experienced team of surgeons, medical oncologists, radiation therapists and supportive care providers – all of whom are specialized penile cancer doctors – review each patient’s case to determine the best options. This team then reviews each patient’s progress at weekly tumor board meetings.